2022
Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events
Brongiel S, Rychalsky K, Luon D, Johnson A, Price C, Abdelghany O. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Annals Of Pharmacotherapy 2022, 57: 148-155. PMID: 35656843, DOI: 10.1177/10600280221094330.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsInstitutional review boardImmunosuppressive therapyAdverse eventsSymptom resolutionImmune-related adverse eventsSecond-line immunosuppressive therapyRetrospective medical record reviewSecond-line medicationsCommon Terminology CriteriaSecond-line therapySecond-line treatmentMedical record reviewDose of infliximabHigh response rateUniversity Institutional Review BoardGastrointestinal ImmuneIrAE treatmentSteroid failureTerminology CriteriaCheckpoint inhibitorsMost patientsRecord reviewInclusion criteriaPatients
2020
Optimizing Care for Patients With Adverse Events From Immunotherapeutics.
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/ppo.0000000000000492.BooksConceptsImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsImmune therapyGuideline-driven managementMajority of irAEsSteroid-refractory casesRisk patientsOptimal carePredictive biomarkersTumor boardIrAEsWellness clinicPatientsEarly detectionTranslational researchTherapyCareCommon occurrenceInhibitorsImmunotherapeuticsClinicSteroidsImmuneBiomarkersTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes